Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation- An Observational, Multi-Center Study

Trial Profile

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation- An Observational, Multi-Center Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms CITRIN
  • Sponsors AbbVie
  • Most Recent Events

    • 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 23 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top